ALK-Abelló B Logo
DK0060027142
A0H0J1
ALK-B.CO

ALK-Abelló B

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Alk-Abello expects quarterly results on Nov. 17, analysts see revenue and earnings rise

    Alk-Abello will release results for the quarter ended Sept. 30 on Nov. 17. One analyst estimates EPS at 1.70 DKK versus 1.42 DKK a year earlier; four analysts expect revenue to rise by 13.6% to an average of 1.74 billion DKK (prior year 1.53 billion DKK). For the current fiscal year, analysts on average forecast EPS of 6.73 DKK (prior year 5.40 DKK) and revenue of 7.29 billion DKK (prior year 6.31 billion DKK). » More on finanzen.net


  • ALK Abelló shares fall premarket despite strong Q2 growth

    ALK Abelló reported currency-adjusted sales growth of 18% in Q2 to around DKK 1.8 billion and EBIT up 19% with a stable EBIT margin of 25%. The company lifted the lower end of its full-year revenue guidance to currency-adjusted growth of 14–16% and expects free cash flow of more than DKK 1 billion. However, investors reacted to missing comparable EPS figures, continued spending on growth initiatives and a more cautious tone for the top end of the guidance, sending the stock down about 6.35% in premarket trading. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, ALK-Abelló B has already paid €1.38 in dividends. The last payout was in March.

Financials

In the last quarter, ALK-Abelló B had revenue of €235.97m and net profit of €48.42m

(EUR) September 2026
YoY
Revenue 235.97m 15.12%
Gross profit 159.99m 14.50%
Net profit 48.42m 15.11%
EBITDA 76.11m 11.40%

Fundamentals

Metric Value
Market capitalization
€7.27bn
Number of shares
221.88m
52-week high/low
€36.30 - €25.65
Dividend yield
4.19%
Dividends TTM
€1.38
Beta
0.68
P/E ratio
38.70
PEG ratio
1.41
P/B ratio
7.47
P/S ratio
7.70

Company profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Name
ALK-Abelló B
CEO
Peter Halling
Headquarters Horsholm, cr
Denmark
Website
IPO
10/03/2000
Employees 2,773

Ticker symbols

Exchange Symbol
Nasdaq Copenhagen
ALK-B.CO
🍪

Parqet  uses cookies. Learn more